Filing date | Form | Description | Filing Group | View |
---|---|---|---|---|
10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | |
10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | |
10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
10-Q/A | Amendment to a previously filed 10-Q |
Quarterly Filings
|
||
144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.